PROMOMED announces the launch of a long-term management motivation program with share buyback tools

June 30, 2025, Moscow - PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries– the "Group") announces the launch of a long–term management motivation program (hereinafter referred to as the Program) with share repurchase instruments (buy-back).

The program was approved by the Board of Directors of PROMOMED in order to increase the return on equity investments. The program is aimed at accelerating the growth of the Group's shareholder value through the motivation of key top managers of the Company in the medium and long term and is a logical stage in the development of PROMOMED as a new generation company: innovative, responsible and result-oriented.

The main Program parameters:

• Validity period: for 36 months (until August 2028);
• The main implementation tool: share repurchase, during the entire duration of the Program;
• The maximum number of shares acquired under the Program is less than 1% of the total current number of shares of the Company.;
• The key managers of the Company will be able to use the Program when the targets approved by the Board of Directors are achieved by the end of 2024-2027.

The buyback parameters during the Program period ensure that the interests of all parties are respected: current shareholders and Program participants. Program participants get access to tools to participate in the growth of shareholder value, while the Company's capital structure remains unchanged, without diluting the shares of existing shareholders.

Member of the Board of Directors of PJSC PROMOMED, Yuri Troyankin, commented: "Our employees and our talents are both a key resource and the driving force behind everything we create as part of our growth strategy. True innovation requires not only expertise, but also a high degree of engagement. The announced Program solves these tasks by increasing the financial interest of our employees in the growth of the Group's shareholder value and at the same time creates the best conditions for attracting, retaining and motivating specialists who can increase the Company's shareholder value and give a new additional impetus to the Group's development. Long—term motivation is about partnership and co-authorship in the development of a Company that is ahead and will be ahead of the growth of the pharmaceutical market."

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. In 2025, PROMOMED celebrates the 20th anniversary of the Company's founding.  

The Company's structure includes its own unique world-class R&D center and a high-tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts:

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• an offer to purchase medicines,
• advertising of medicines,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the sole source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions contained in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.